About Palisade Bio
Palisade Bio is a company based in Carlsbad (United States) founded in 2005. The company has 8 employees as of December 31, 2024. Palisade Bio offers products and services including PDE4 Platform and PALI-2108. Palisade Bio operates in a competitive market with competitors including EsoCap Biotech, Nucliqbio, CJ HealthCare, Amyra and Carbiotix, among others.
- Headquarter Carlsbad, United States
- Employees 8 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Palisade Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$14.44 M (USD)-17.23as on Dec 31, 2024
-
EBITDA
-$14.86 M (USD)-15.69as on Dec 31, 2024
-
Latest Funding Round
$500 K (USD), Post-IPO
Jan 07, 2026
-
Investors
HHS
& 2 more
-
Employee Count
8
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Palisade Bio
Palisade Bio is a publicly listed company on the NASDAQ with ticker symbol PALI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Palisade Bio
Palisade Bio offers a comprehensive portfolio of products and services, including PDE4 Platform and PALI-2108.
Technology for developing precision therapies in medicine
Pipeline product for ulcerative colitis treatment
People of Palisade Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Palisade Bio
Investors in Palisade Bio
Palisade Bio has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Onvida Health and Crohn's & Colitis Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Onvida Health is recognized for providing comprehensive healthcare services.
|
Locked | Locked | Locked |
Investor details for Palisade Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Palisade Bio
Investment portfolio details for Palisade Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Palisade Bio
Detailed financials for Palisade Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Palisade Bio Comparisons
Peer comparison for Palisade Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Palisade Bio
Palisade Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EsoCap Biotech, Nucliqbio, CJ HealthCare, Amyra and Carbiotix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Topical drug delivery platform for upper GI disorders is developed.
|
|
| Locked | Locked | Locked |
Therapeutic drugs for gut health are developed using metagenomics.
|
|
| Locked | Locked | Locked |
Developer of therapies for treating gastrointestinal disorders
|
|
| Locked | Locked | Locked |
Pioneers enzyme supplementation for general health, nutrition, and food sensitivities.
|
|
| Locked | Locked | Locked |
Prebiotic ingredients and consumer products for microbiome health are developed.
|
Detailed competitors of Palisade Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Palisade Bio
Complete news archive for Palisade Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Palisade Bio
Palisade Bio was founded in 2005 and raised its 1st funding round 12 years after it was founded.
Palisade Bio is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Thomas Hallam is the current CEO of Palisade Bio.
As of Dec 31, 2024, the latest employee count at Palisade Bio is 8.
Palisade Bio was founded in 2005 and is based in Carlsbad, United States. Operations focus on the biotechnology sector, where therapeutics for gastrointestinal disorders are developed. The lead candidate, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug targeted at moderate-to-severe ulcerative colitis. Another drug, GT-1908, addresses fibrostenotic Crohns disease. Development activities center on advancing these prodrugs through clinical stages.
Palisade Bio's top competitors include Carbiotix, EsoCap Biotech and CJ HealthCare.
Palisade Bio offers PDE4 Platform and PALI-2108.
Yes, Palisade Bio is publicly traded on NASDAQ under the ticker symbol PALI.
Palisade Bio has 3 investors. Key investors include HHS, Onvida Health, and Crohn's & Colitis Foundation.
The ticker symbol of Palisade Bio is PALI on NASDAQ.